Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roivant Sciences Ltd (NQ: ROIV )

9.410 +0.320 (+3.52%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,063,606
Open 9.130
Bid (Size) 9.030 (10)
Ask (Size) 9.430 (1)
Prev. Close 9.090
Today's Range 9.130 - 9.560
52wk Range 4.980 - 13.24
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
From Roivant Sciences
Via GlobeNewswire
Why Is Vivek Ramaswamy-Founded Roivant Sciences Stock Trading Lower Today?
Roivant Sciences Ltd (NASDAQ: ROIV) and Priovant's Phase 2 study of oral brepocitinib in moderate to severe active lupus did not meet its primary endpoint of Systemic Lupus Erythematosus (SLE)  
Via Benzinga

Performance

YTD
+31.61%
+31.61%
1 Month
+11.36%
+11.36%
3 Month
-16.36%
-16.36%
6 Month
-5.14%
-5.14%
1 Year
+86.71%
+86.71%

More News

Read More
Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus
From Roivant Sciences
Via GlobeNewswire
8 Analysts Have This to Say About Roivant Sciences
Via Benzinga
Roivant Sciences Earnings Preview
Via Benzinga
What 8 Analyst Ratings Have To Say About Roivant Sciences
Via Benzinga
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors
From Roivant Sciences
Via GlobeNewswire
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023
From Roivant Sciences
Via GlobeNewswire
Earnings Scheduled For November 13, 2023
Via Benzinga
It's Hard to Be a Biotech Bull in This Market, but This Stock Is a Buy
Via The Motley Fool
FSR Stock Alert: What to Know as Fisker Drops Prices
Via InvestorPlace
PINS Stock Pops as Stifel Upgrades Pinterest
Via InvestorPlace
Why Is Roivant Sciences (ROIV) Stock Up Today?
Via InvestorPlace
Roche Spends $7.1 Billion On Roivant Drug, Following Merck, Sanofi Into The Raging Hot Immunology Space
Via Investor's Business Daily
Roche Buys Pfizer & Roivant Sciences' Televant In ~$7.1B Deal
Via Benzinga
Why Troika Media Group Shares Are Trading Lower By Over 20%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Textainer Group, Roivant Sciences And Other Big Stocks Moving Higher In Monday's Pre-Market Session
Via Benzinga
Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant
From Roivant Sciences
Via GlobeNewswire
Covant Therapeutics Appoints Vincent Hennemand as Chief Executive Officer
From Covant Therapeutics
Via GlobeNewswire
Teva Pharma Hooks Sanofi In $1.5 Billion Inflammation Deal. But Shares Tumble.
Via Investor's Business Daily
3 No-Brainer Growth Stocks to Buy in October
Via The Motley Fool
Why Immunovant Stock Is Bolting Higher Today
Via The Motley Fool
Johnson Controls International To Rally Over 27%? Here Are 10 Other Analyst Forecasts For Wednesday
Via Benzinga
Roivant Stock Price Outlook: Strong Pipeline Is A Catalyst
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.